Breast cancer battleground drug not a game-changer when given for a year

UPDATED: This article has been updated to clarify the study’s initial point of enquiry, and to add a reference to disease recurrence
+Practice

Breast cancer battleground drug not a game-changer when given for a year

woman with cancer iStock
A small proportion of patients do better with the longer course of Herceptin, but there are disadvantages
US oncologists are reporting a trial of the breast cancer drug trastuzumab (Herceptin) has failed to demonstrate one year is significantly better than